# Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation

Study · id `cardio:ct-nct01332747` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01332747](<https://clinicaltrials.gov/study/NCT01332747>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01332747

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

## Technical summary

Registry record NCT01332747. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 128 participants (enrolled count; ClinicalTrials.gov record NCT01332747, source copy `cardio:ctgov-nct01332747-2014-10-21`, retrieved 2026-10-31)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01332747, source copy `cardio:ctgov-nct01332747-2014-10-21`, retrieved 2026-10-31)
- Primary completion: 2011-05 (actual) (ClinicalTrials.gov record NCT01332747, source copy `cardio:ctgov-nct01332747-2014-10-21`, retrieved 2026-10-31)
- Completion: 2011-05 (actual) (ClinicalTrials.gov record NCT01332747, source copy `cardio:ctgov-nct01332747-2014-10-21`, retrieved 2026-10-31)
- Countries: India (ClinicalTrials.gov record NCT01332747, source copy `cardio:ctgov-nct01332747-2014-10-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01332747-2014-10-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation
- Condition: Hyperlipidemia
- Intervention (Drug): safoof e muhazzil
- Intervention (Drug): compressed tablet of safoof e muhazzil
- Intervention (Drug): Atorvastatin
- Lead sponsor: Jamia Hamdard University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)

## Provenance

Content hash: f4c9886be04956455b2efe2b6770f626c1c355f324968829a27071251a8b1a10
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
